E expression biomarkers which were associated with each single drug sensitivity

E expression biomarkers which were associated with each single drug sensitivity and independent of other known biological factors correlated withTable 4. Clinical response rates of COXEN-matched vs. unmatched patient groups in the TCGA cohort after the primary platinumbased chemotherapy.Drug response after first-line chemotherapy Drug Assignment Matched COXEN Guided drug PaclitaxelaResponder (row ) 64(80.0 ) 1(50 ) ?65(79.3 ) 0 111 (67.7 ) 10 (62.5 ) 121 (66.9 )Nonresponder 16 1 ?17 1 53 6Missing 10 1 ?111 ?31 3Total 90 3 ?93 1 195 19Cyclophosphamide Topotecan BX795 side effects Subtotal Unmatched Paclitaxel Cyclophosphamide Topotecan SubtotalaAlmost all patients were treated with paclitaxel in the first-line chemotherapy, so the matched patients were predicted to have the highest survival benefit from the drug (of the three) and the unmatched patients were predicted to have the highest survival benefit from the other two drugs. doi:10.1371/journal.pone.0086532.tPLOS ONE | www.plosone.orgSurvival Improvement by Personalized ChemotherapyFigure 3. Kaplan-Meier survival stratification between COXEN-matched and unmatched patients in the TCGA-448 cohort. (A) OS difference between matched and unmatched patients, (B) PFS difference between matched and unmatched patients, (C) OS difference between matched and unmatched patients among recurrent EOC patients. doi:10.1371/journal.pone.0086532.gdrug response. A further triage of these initial biomarkers for direct association with patient survival then allowed us to select the final single-drug biomarkers that were also relevant to human patient outcomes. We first found that these COXEN Necrostatin-1 chemical information predictors independently showed high prediction for both patient short-term therapeutic response and long-term survival. We then examined the potential benefit from a personalized treatment use of the three drug predictors on the TCGA cohort of 443 EOC patients from .10 clinical centers. Following the FDA guideline for statistical evaluation of diagnostic predictors (FDA Docket No. 2003D0044), we independently examined these predictors in a prospective manner on the patient tumors from the primary surgery prior to systemic therapy. From this prospective testing we found that both overall survival and PFS of the cohort were significantly prolonged when patients had been treated with the predicted most beneficial drugs. When this benefit was examined for patients with recurrent EOC, overall survival was 21 months longer for the patients treated with the drugs predicted to be the most beneficial drugs (COXEN-matched) than the patients treated with other drugs (COXEN-unmatched). Survival improvement was greater for the platinum-sensitive patients than the platinum-resistant patients. We closely examined whether our COXEN models were merely prognostic predictors that selected patients simply with longer survival irrelevant to the specific drug treatments. We directly investigated this issue by comparing the survival difference among the patients who were not treated with the respective drugs, and confirmed that even if patients had higher COXEN scores, they showed neither better therapeutic response nor longer survival unless they were treated with the predicted effective drugs. Also, in order to examine whether these survival difference observed by the COXEN stratification was due to any other confounding factors,we compared the distributions of all available clinicopathological variables such as tumor stage and age between the COXEN mat.E expression biomarkers which were associated with each single drug sensitivity and independent of other known biological factors correlated withTable 4. Clinical response rates of COXEN-matched vs. unmatched patient groups in the TCGA cohort after the primary platinumbased chemotherapy.Drug response after first-line chemotherapy Drug Assignment Matched COXEN Guided drug PaclitaxelaResponder (row ) 64(80.0 ) 1(50 ) ?65(79.3 ) 0 111 (67.7 ) 10 (62.5 ) 121 (66.9 )Nonresponder 16 1 ?17 1 53 6Missing 10 1 ?111 ?31 3Total 90 3 ?93 1 195 19Cyclophosphamide Topotecan Subtotal Unmatched Paclitaxel Cyclophosphamide Topotecan SubtotalaAlmost all patients were treated with paclitaxel in the first-line chemotherapy, so the matched patients were predicted to have the highest survival benefit from the drug (of the three) and the unmatched patients were predicted to have the highest survival benefit from the other two drugs. doi:10.1371/journal.pone.0086532.tPLOS ONE | www.plosone.orgSurvival Improvement by Personalized ChemotherapyFigure 3. Kaplan-Meier survival stratification between COXEN-matched and unmatched patients in the TCGA-448 cohort. (A) OS difference between matched and unmatched patients, (B) PFS difference between matched and unmatched patients, (C) OS difference between matched and unmatched patients among recurrent EOC patients. doi:10.1371/journal.pone.0086532.gdrug response. A further triage of these initial biomarkers for direct association with patient survival then allowed us to select the final single-drug biomarkers that were also relevant to human patient outcomes. We first found that these COXEN predictors independently showed high prediction for both patient short-term therapeutic response and long-term survival. We then examined the potential benefit from a personalized treatment use of the three drug predictors on the TCGA cohort of 443 EOC patients from .10 clinical centers. Following the FDA guideline for statistical evaluation of diagnostic predictors (FDA Docket No. 2003D0044), we independently examined these predictors in a prospective manner on the patient tumors from the primary surgery prior to systemic therapy. From this prospective testing we found that both overall survival and PFS of the cohort were significantly prolonged when patients had been treated with the predicted most beneficial drugs. When this benefit was examined for patients with recurrent EOC, overall survival was 21 months longer for the patients treated with the drugs predicted to be the most beneficial drugs (COXEN-matched) than the patients treated with other drugs (COXEN-unmatched). Survival improvement was greater for the platinum-sensitive patients than the platinum-resistant patients. We closely examined whether our COXEN models were merely prognostic predictors that selected patients simply with longer survival irrelevant to the specific drug treatments. We directly investigated this issue by comparing the survival difference among the patients who were not treated with the respective drugs, and confirmed that even if patients had higher COXEN scores, they showed neither better therapeutic response nor longer survival unless they were treated with the predicted effective drugs. Also, in order to examine whether these survival difference observed by the COXEN stratification was due to any other confounding factors,we compared the distributions of all available clinicopathological variables such as tumor stage and age between the COXEN mat.